Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197348 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2TLR2ALDH1A1 | |
| SCHEMBL26045825 | 0.98 | LPAR1 (0.60) | LPAR1LPAR3LPAR2TLR2PLA2G2C | |
| SCHEMBL15158724 | 0.98 | LPAR1 (0.60) | LPAR1LPAR3LPAR2TLR2PLA2G2C | |
| SCHEMBL8746910 | 0.90 | LPAR1 (0.52) | LPAR1LPAR3LPAR2TLR2ALDH1A1 | |
| SCHEMBL30385293 | 0.90 | PRKCA (0.57) | LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL13224996 | 0.89 | ALDH1A1 (0.59) | LPAR1LPAR3LPAR2TLR2ALDH1A1 | |
| SCHEMBL2232552 | 0.87 | PLA2G2C (0.53) | LPAR1LPAR3LPAR2TLR2ALDH1A1 | |
| SCHEMBL8746900 | 0.87 | PLA2G2C (0.53) | LPAR1LPAR3LPAR2TLR2ALDH1A1 | |
| SCHEMBL8746903 | 0.86 | PLA2G2C (0.55) | LPAR1LPAR3LPAR2TLR2PLA2G2C | |
| SCHEMBL10105551 | 0.86 | ALDH1A1 (0.45) | LPAR1LPAR3LPAR2TLR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071105-A1 | JACKFRUIT FLOUR FOR REDUCING CHEMOTOXICITY AND USES THEREOF | GOD'S OWN FOOD SOLUTIONS PVT. LTD (IN) | 2023-03-09 | — | — | US | disclosed |
| US-11357749-B2 | Methods for treating neutropenia | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2022-06-14 | — | — | US | disclosed |
| US-11357749-B2 | Methods for treating neutropenia | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2022-06-14 | — | — | US | disclosed |
| CN-114081876-A | Methods of treating leukopenia and thrombocytopenia | 株式会社Enzychem生命科学 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021152639-A1 | JACKFRUIT FLOUR FOR REDUCING CHEMOTOXICITY AND USES THEREOF | GOD'S OWN FOOD SOLUTIONS PVT. LTD (IN) | 2021-08-05 | — | — | WO | disclosed |
| US-20200289451-A1 | METHODS FOR TREATING THROMBOCYTOPENIA | ENZYCHEM LIFESCIENCES CORP (KR) | 2020-09-17 | — | — | US | disclosed |
| US-20200289451-A1 | METHODS FOR TREATING THROMBOCYTOPENIA | ENZYCHEM LIFESCIENCES CORP (KR) | 2020-09-17 | — | — | US | disclosed |
| US-20200222355-A1 | METHODS FOR TREATING NEUTROPENIA | ENZYCHEM LIFESCIENCES CORP (KR) | 2020-07-16 | — | — | US | disclosed |
| US-20200222355-A1 | METHODS FOR TREATING NEUTROPENIA | ENZYCHEM LIFESCIENCES CORP (KR) | 2020-07-16 | — | — | US | disclosed |
| US-10653657-B2 | Method for treating hemolytic uremic syndrome | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2020-05-19 | — | — | US | disclosed |
| US-20160128966-A1 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2016-05-12 | — | — | US | disclosed |
| WO-2015176012-A1 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015176012-A1 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2015-11-19 | — | — | WO | disclosed |
| US-20150266803-A1 | METHOD FOR PREPARING MONOACETYGLYCEROLS AND ESTERS THEREOF | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266803-A1 | METHOD FOR PREPARING MONOACETYGLYCEROLS AND ESTERS THEREOF | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2015-09-24 | — | — | US | disclosed |
| US-7429473-B2 | Diacylglycerol acyltransferase genes, proteins, and uses thereof | MICHIGAN STATE UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070028329-A1 | Diacylglycerol acyltransferase genes, proteins, and uses thereof | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2007-02-01 | — | — | US | disclosed |
| US-7122367-B2 | Diacylglycerol acyltransferase genes, proteins, and uses thereof | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050130284-A1 | Diacylglycerol acyltransferase genes, proteins, and uses thereof | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY, THE | 2005-06-16 | — | — | US | disclosed |
| EP-1484392-A1 | Diacylglycerol acyltransferase genes, proteins and uses thereof | Board of Trustees Operating Michigan State University (US) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653657-B2 | Method for treating hemolytic uremic syndrome | LCAT, LPCAT1, SGMS1 | LPAR1 116/4885LPAR3 128/4885LPAR2 103/4885 |
| US-11357749-B2 | Methods for treating neutropenia | DAGLA, DAGLB, PNLIP | LPAR1 736/4885LPAR3 909/4885LPAR2 659/4885 |
| US-20200289451-A1 | METHODS FOR TREATING THROMBOCYTOPENIA | DAGLA, PHOSPHO1, DAGLB | LPAR1 438/4885LPAR3 534/4885LPAR2 315/4885 |
| US-20200222355-A1 | METHODS FOR TREATING NEUTROPENIA | DAGLA, DAGLB, PNLIP | LPAR1 736/4885LPAR3 909/4885LPAR2 659/4885 |
| US-20150266803-A1 | METHOD FOR PREPARING MONOACETYGLYCEROLS AND ESTERS THEREOF | ABHD5, DGAT2, MOGAT2 | LPAR1 242/4885LPAR3 258/4885LPAR2 168/4885 |
| US-20160128966-A1 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA | DAGLA, PHOSPHO1, THPO | LPAR1 273/4885LPAR3 436/4885LPAR2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.